Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics

Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Hongkai, Guo, Yi, Chang, Mei H., McSweeney, Terrence, Golia, Austin M., Cowman, Kelsie, Bartash, Rachel, Anosike, Brenda I., Nori, Priya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726567/
https://www.ncbi.nlm.nih.gov/pubmed/36483336
http://dx.doi.org/10.1017/ash.2022.52
_version_ 1784844818109693952
author Bao, Hongkai
Guo, Yi
Chang, Mei H.
McSweeney, Terrence
Golia, Austin M.
Cowman, Kelsie
Bartash, Rachel
Anosike, Brenda I.
Nori, Priya
author_facet Bao, Hongkai
Guo, Yi
Chang, Mei H.
McSweeney, Terrence
Golia, Austin M.
Cowman, Kelsie
Bartash, Rachel
Anosike, Brenda I.
Nori, Priya
author_sort Bao, Hongkai
collection PubMed
description Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.
format Online
Article
Text
id pubmed-9726567
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-97265672022-12-07 Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics Bao, Hongkai Guo, Yi Chang, Mei H. McSweeney, Terrence Golia, Austin M. Cowman, Kelsie Bartash, Rachel Anosike, Brenda I. Nori, Priya Antimicrob Steward Healthc Epidemiol Review Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program. Cambridge University Press 2022-04-29 /pmc/articles/PMC9726567/ /pubmed/36483336 http://dx.doi.org/10.1017/ash.2022.52 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Review
Bao, Hongkai
Guo, Yi
Chang, Mei H.
McSweeney, Terrence
Golia, Austin M.
Cowman, Kelsie
Bartash, Rachel
Anosike, Brenda I.
Nori, Priya
Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics
title Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics
title_full Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics
title_fullStr Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics
title_full_unstemmed Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics
title_short Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics
title_sort expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (covid-19) therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726567/
https://www.ncbi.nlm.nih.gov/pubmed/36483336
http://dx.doi.org/10.1017/ash.2022.52
work_keys_str_mv AT baohongkai expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics
AT guoyi expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics
AT changmeih expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics
AT mcsweeneyterrence expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics
AT goliaaustinm expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics
AT cowmankelsie expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics
AT bartashrachel expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics
AT anosikebrendai expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics
AT noripriya expandingthescopeandvisibilityofambulatorystewardshipprogramswithnovelcoronavirusdisease2019covid19therapeutics

Ejemplares similares